Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Eli Lilly (NYSE:LLY) focuses on researching, developing, and bringing to market a wide range of medicines, including ...

Eli Lilly acquires SiteOne Therapeutics for up to $1B, signaling potential uptick in Big Pharma deals and focus on non-opioid ...

The stock's rise snapped a five-day losing streak.

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Eli Lilly has agreed to acquire the pain-treatment company SiteOne Therapeutics for up to $1 billion in cash. The drug company said Tuesday that the acquisition includes SiteOne's STC-004, which is ...

Plus, hedge fund investor Ken Griffin gave $10 million to NYU Langone Health to create a center that will offer programs ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...